Pic Credit: Financial Express
The clinical trials of the COVID-19 vaccine candidate being developed by Oxford University and AstraZeneca may have been put on pause following an adverse reaction observed in one of the participants in the UK, but that’s not going to affect the vaccine’s trials in India.
“This incident in the UK will have no impact on the Indian vaccine trial being carried out by Serum Institute,” said CEO of Serum Institute of India (SII) Adar Poonawalla.
SII is partnering University of Oxford’s Jenner Institute in conducting trials of the vaccine AZD1222 (aka ChAdOx1 nCoV-19) in India, also known as COVISHIELD.
SII trials are currently taking place in 17 sites, each with over 1,000 patients.
“Nothing untoward has been reported during the vaccine trials in India,” Poonawalla told India Today on Wednesday.
“The reaction that has been reported is not directly linked to the vaccine. The person who has had the reaction had an existing neurological condition. During a vaccine trial such events are common place,” he said.
On an encouraging note, he further said, “Our production timelines are on schedule as planned.”
Also Read: Serum Institute Starts Phase 2 Trial Of Oxford COVID-19 Vaccine Candidate Today
Berhampur: Continuing to target places of worship in different parts of Odisha, burglars struck at…
New York: US President-elect Donald Trump has nominated an Indian American entrepreneur and former aide…
New Delhi: BJP MPs Pratap Sarangi and Mukesh Rajput, who suffered head injuries in the…
Pune: Three people, including two toddlers, died on Monday when a dumper truck run over…
Lucknow: Three terrorists accused of lobbing a grenade at a police post in Punjab’s Gurdaspur…
Malkangiri: If things go as per plan, flight services between Odisha’s Malkangiri town and Visakhapatnam…
This website uses cookies.